Apararenone
Nonsteroidal antimineralocorticoid
Clinical data | |
---|---|
Other names | MT-3995 |
Routes of administration | Oral |
Drug class | Antimineralocorticoid |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C17H17FN2O4S |
Molar mass | 364.39 g·mol−1 |
3D model (JSmol) |
|
| |
InChI
|
Apararenone (INN) (developmental code name MT-3995) is a nonsteroidal antimineralocorticoid which is under development by Mitsubishi Tanabe Pharma for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.[1][2][3] It was also previously being developed for the treatment of hypertension, but development was discontinued for this indication.[1] Apararenone acts as a highly selective antagonist of the mineralocorticoid receptor (Ki < 50 nM), the receptor for aldosterone.[1][2][3] As of 2017, it is in phase II clinical trials.[1]
See also
References
- ^ a b c d "Apararenone - Mitsubishi Tanabe Pharma - AdisInsight".
- ^ a b Yang J, Young MJ (2016). "Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences". Curr Opin Pharmacol. 27: 78–85. doi:10.1016/j.coph.2016.02.005. PMID 26939027.
- ^ a b Kolkhof P, Nowack C, Eitner F (2015). "Nonsteroidal antagonists of the mineralocorticoid receptor". Curr. Opin. Nephrol. Hypertens. 24 (5): 417–24. doi:10.1097/MNH.0000000000000147. PMID 26083526. S2CID 22113501.
External links
- Apararenone - AdisInsight
- v
- t
- e
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Mineralocorticoid receptor modulators
- Glucocorticoids and antiglucocorticoids
- List of corticosteroids
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e